What David Sinclair's Reported Protocol Might Look Like Clinically

By
Published Updated Last reviewed
Medical lab testing image for What David Sinclair's Reported Protocol Might Look Like Clinically

At a glance

  • Public status: All three compounds confirmed by Sinclair in writing and on-camera
  • Compounds: NMN (NAD+ precursor), metformin (off-label, biguanide), resveratrol (polyphenol)
  • Confirmed doses: NMN ~1 g/day, metformin ~1 g/day, resveratrol ~1 g/day with yogurt (per Lifespan and podcast statements)
  • Evidence tier: Promising preclinical data; limited but growing human RCT evidence
  • FDA status: NMN and resveratrol are supplements, not approved drugs; metformin is FDA-approved for type 2 diabetes only
  • Key clinical gap: No large, long-term human RCT has confirmed mortality or healthspan benefit for any of these three compounds in non-diabetic adults

Who Is David Sinclair and Why Does His Protocol Matter?

David Sinclair is not a celebrity in the traditional entertainment sense. He is a scientist whose public profile has grown to the point where his personal health choices reach millions of people and directly shape supplement market demand. His laboratory at Harvard has produced influential work on sirtuins, NAD+ metabolism, and epigenetic clocks. His 2019 book Lifespan: Why We Age and Why We Don't Have To became a bestseller, and in it he disclosed his personal regimen with unusual specificity for a sitting academic.

That specificity is precisely why clinical translation matters here. When a Harvard professor with genuine domain expertise says he takes a gram of metformin every day for longevity, a large portion of readers will reasonably ask: should I? The HealthRX Medical Team's job is not to endorse or dismiss that question but to give you the scaffolding to answer it with your own physician.

What Sinclair Has Actually Confirmed (The Public Record)

In Lifespan (Simon & Schuster, 2019), Sinclair wrote in the first person that he takes 1 gram of NMN every morning, 1 gram of resveratrol with yogurt (he has noted fat enhances resveratrol absorption), and 1 gram of metformin at night, with the caveat that he skips metformin on days he exercises intensely due to concerns about blunting exercise adaptation. He has repeated these disclosures on The Joe Rogan Experience, the Huberman Lab podcast, and in numerous media interviews through 2023.

He has also publicly confirmed taking vitamin D3, vitamin K2, aspirin (81 mg), and a statin, and he has discussed having his biological age assessed using epigenetic clocks. Those additional compounds are outside the scope of this page, but the pattern is consistent: Sinclair is unusually transparent about his personal protocol by academic standards.

No private medical records have been reviewed. Everything reported here comes from his own public statements.

NMN: The NAD+ Precursor

Mechanism

Nicotinamide mononucleotide is a direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential to mitochondrial energy metabolism, DNA repair, and the activation of sirtuins (SIRT1-7), a family of deacetylases Sinclair's lab has spent two decades studying. NAD+ levels decline with age in multiple tissues, a finding replicated across species. The premise of NMN supplementation is that orally raising NAD+ precursor availability can slow or partially reverse that decline.

In rodent models, NMN supplementation has shown improvements in muscle function, energy metabolism, insulin sensitivity, and longevity-associated markers. A 2013 Cell paper from the Sinclair lab demonstrated that raising NAD+ in aged mice restored aspects of vascular and muscle function to a more youthful state, a finding that attracted substantial attention.

Human Evidence

Human RCT data is more limited but growing. A 2022 randomized controlled trial published in Science (iScience) found that oral NMN at 250 mg/day for 10 weeks increased blood NAD+ levels and improved muscle insulin sensitivity and signaling in postmenopausal women with prediabetes. A 2021 RCT in npj Aging confirmed that NMN at 250 mg/day was safe and raised whole-blood NAD+ in healthy older adults. Neither trial measured hard clinical endpoints like mortality, cardiovascular events, or functional decline over time.

Dose and Practical Considerations

Sinclair's confirmed dose of 1 gram/day is four times the dose used in most published human trials. No safety signal has emerged at this dose in published work, but formal dose-ranging safety studies at 1 g/day in large cohorts have not been completed. The HealthRX Medical Team notes that "safe in small short trials" and "safe at higher doses long-term" are meaningfully different statements.

NMN is sold as a dietary supplement in the United States. The FDA issued a warning in 2022 that certain NMN products were being improperly marketed, and the regulatory status of NMN as a supplement versus a new dietary ingredient has been contested. Buyers should verify third-party testing for purity and actual NMN content.

Metformin: The Most Clinically Interesting Component

Why Metformin for Longevity?

Metformin is FDA-approved for type 2 diabetes management, where its safety record across 60-plus years is well established. Its potential longevity applications rest on a different mechanistic foundation. Metformin activates AMPK (AMP-activated protein kinase), a cellular energy sensor that, when activated, inhibits mTORC1 and promotes autophagy, two pathways strongly associated with longevity in model organisms. It also reduces hepatic glucose production, lowers circulating insulin, and has shown anti-inflammatory effects independent of glucose lowering.

Observational data from diabetic cohorts has suggested that metformin-treated patients sometimes live longer than non-diabetic controls, a counterintuitive finding that generated significant scientific interest. This led to the design of the TAME trial (Targeting Aging with Metformin), a multi-site NIH-funded RCT specifically testing whether metformin delays aging-related disease in non-diabetic adults. TAME is ongoing; results are not yet available.

Off-Label Prescribing in Non-Diabetic Adults

No physician can currently prescribe metformin for longevity on the basis of an approved indication. Off-label prescribing is legal in the United States, but prescribers take on the responsibility of informed consent and must weigh benefit against risk in the absence of RCT data in this population. Sinclair has never publicly disclosed how he obtained his metformin prescription, though he has described discussing it with his doctor.

Common side effects include gastrointestinal symptoms (nausea, diarrhea) in 20-30% of patients, particularly at initiation. The extended-release formulation reduces GI burden. Rare but serious risks include lactic acidosis, primarily in patients with renal impairment. Metformin is contraindicated when eGFR falls below 30 mL/min/1.73m2. FDA prescribing information should be reviewed in full.

Sinclair's public comment about skipping metformin on exercise days reflects a real concern. A 2022 paper in Nature Aging found that metformin blunted aerobic fitness gains from exercise training in older adults, a finding that adds genuine nuance to the risk-benefit calculation for physically active users.

The HealthRX Medical Team's view: metformin is the most evidence-supported component of Sinclair's confirmed regimen in terms of mechanism and human safety data, but it remains off-label for longevity. The TAME trial results will be critical. Until those data exist, any non-diabetic adult considering this use needs a careful conversation with a physician who knows their renal function, medication list, and baseline metabolic status.

Resveratrol: The Sirtuin Activator With a Complicated History

Mechanism and the Sirtuin Hypothesis

Resveratrol is a polyphenol found in grape skins and red wine. Sinclair's early research identified it as a direct activator of SIRT1, a sirtuin he has argued is a master regulator of aging-related gene expression. A landmark 2006 Nature paper showed resveratrol extended lifespan in obese mice on a high-fat diet. The findings generated enormous excitement and helped launch the field Sinclair now occupies.

The sirtuin-activation mechanism was later disputed. A 2010 paper in Journal of Biological Chemistry and subsequent work found that earlier assays used a fluorescent tag that artificially amplified SIRT1 activation. The debate over whether resveratrol directly activates sirtuins in physiologically relevant ways in humans has not been fully resolved.

Human Evidence

Human RCT results have been mixed. Some trials have shown improvements in glucose metabolism, blood pressure, and inflammatory markers. Others have shown no effect or even adverse interactions. A 2013 JAMA Internal Medicine study found that resveratrol supplementation did not improve cardiovascular risk factors in older adults with stable coronary artery disease, conflicting with earlier optimism. Bioavailability is a persistent issue: resveratrol is rapidly metabolized after oral ingestion, leading to low plasma concentrations unless absorption is enhanced. Sinclair's practice of taking it with yogurt (fat) is consistent with published data showing fat increases absorption, though the clinical significance of that increase remains debated.

At 1 gram/day (Sinclair's confirmed dose), resveratrol is generally considered safe in short-term studies. Higher doses have been associated with GI side effects and, in some trials, adverse effects on insulin sensitivity in specific populations.

What a Prescribing Physician Would Actually Need to Know

Translating Sinclair's confirmed regimen into a clinical protocol for another person requires individualized assessment. A physician considering any version of this approach would evaluate baseline metabolic panels, renal function (critical for metformin), fasting glucose and HbA1c, a complete medication list for interactions (metformin interacts with contrast agents and several drugs affecting renal clearance), cardiovascular status, and the patient's exercise habits given the metformin-exercise adaptation data.

NMN and resveratrol, as supplements, sit outside prescription oversight but carry their own considerations: supplement quality control is not FDA-supervised, so third-party certification (NSF, USP, Informed Sport) matters. The HealthRX Medical Team recommends against treating Sinclair's self-disclosed doses as default starting points. He is a scientist with detailed self-monitoring; his tolerance and individual response may not generalize.

The Honest Bottom Line

Sinclair's public disclosures have done genuine service in bringing NAD+ biology, AMPK signaling, and epigenetic aging research to a mainstream audience. The underlying science is real, published, and peer-reviewed. The gap between "scientifically interesting" and "clinically proven to extend healthy human lifespan" remains large. No compound in his confirmed regimen has yet demonstrated a reduction in all-cause mortality or meaningful healthspan extension in a prospective, randomized, controlled human trial.

That does not make the protocol wrong. It makes it experimental. Sinclair himself has said this repeatedly in public, including on the Lex Fridman Podcast. The appropriate clinical posture is informed experimentation with a physician who can monitor relevant biomarkers, not supplementation based on a celebrity's book.

Frequently asked questions

›Has David Sinclair confirmed all three compounds personally?
›Is metformin legal to take for longevity in the United States?
›Can I buy NMN over the counter?
›Does resveratrol actually activate sirtuins?
›Should I follow Sinclair's protocol?

References

  • Sinclair DA, LaPlante MD. Lifespan: Why We Age and Why We Don't Have To. Atria Books, 2019.
  • Yoshino M et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science (iScience). 2022. https://pubmed.ncbi.nlm.nih.gov/35036862/
  • Gomes AP et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013. https://pubmed.ncbi.nlm.nih.gov/24360282/
  • Yoshino J et al. "NAD+ intermediates: The biology and therapeutic potential of NMN and NR." Cell Metabolism. 2021. https://pubmed.ncbi.nlm.nih.gov/33510399/
  • Kulkarni AS et al. "Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults." Cell Reports Medicine. TAME background. https://pubmed.ncbi.nlm.nih.gov/35316883/
  • Konopka AR et al. "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell. / Nature Aging 2022. https://pubmed.ncbi.nlm.nih.gov/35347278/
  • Lagouge M et al. "Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha." Cell. 2006. https://pubmed.ncbi.nlm.nih.gov/17086191/
  • Patel KR et al. "Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients." Cancer Research. / Bioavailability discussion. https://pubmed.ncbi.nlm.nih.gov/20061386/
  • Bhatt JK et al. "Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus." Nutrition Research. Contrasting trial: https://pubmed.ncbi.nlm.nih.gov/23400120/
  • FDA. Metformin hydrochloride prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf
  • Shaw RJ et al. "The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin." Science. 2005. AMPK/metformin mechanism. https://pubmed.ncbi.nlm.nih.gov/17404297/